Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Intravaginal rings (IVRs) may offer an ideal way to deliver antiretroviral (ARV) drugs to
prevent HIV infection. This study will evaluate the pharmacokinetics and safety of two IVRs
containing different doses of a combination of two HIV ARV drugs, vicriviroc (VCV) (MK-4176)
and MK-2048, in healthy, HIV-uninfected women.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)